Program
HLX37
A development code. Also written as “Investigational drug: HLX37 dose1, IV, Q3W” and “Investigational drug: HLX37 dose2, IV, Q3W”.
In Fosun Pharma's pipeline, PD-L1 x VEGF
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Fosun Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 22 open or running | phase 3since Oct 4, 2026 | Nov 28, 2025 | Mar 30, 2027early phase 1 · NCT07274813 |
- Named in Fosun Pharma’s own pipeline as
HLX37 (PD-L1 x VEGF)
, phase 1, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 28, 2025First study: early phase 1 study in Advanced/Metastatic Solid TumorsFirst studyNCT07274813 · 254 planned · China
- Oct 4, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07865910 · 1,438 planned · China
Ahead
- Mar 30, 2027Primary completion: early phase 1 study in Advanced/Metastatic Solid TumorsNCT07274813
- Dec 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07865910
TargetBeta
“PD-L1 x VEGF”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pumitamig | BioNTech | phase 3 | 34 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07865910Carcinoma, Non-Small-Cell Lung · China | 3 | Not yet recruiting | Dec 30, 2030 | 1,438 |
| NCT07274813Advanced/Metastatic Solid Tumors · China | Early 1 | Recruiting | Mar 30, 2027 | 254 |
How it is read
Names in the registry
- “Investigational drug: HLX37 dose1, IV, Q3W”, 1 entry
- “Investigational drug: HLX37 dose2, IV, Q3W”, 1 entry
- “HLX37”, 1 entry
Codes read as this program: HLX37.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.